Site Map
Site Search
Recent Publications from Our Laboratory
With links to
PubMed and selected article "full texts"
(HTML and PDF
formats.) Please click on the "Full List"
link to view an extended list of publications from this lab.)
The impact of the E46K mutation on the properties of alpha-synuclein in its
monomeric and oligomeric states.
Fredenburg RA, Rospigliosi C, Meray RK, Kessler JC, Lashuel HA, Eliezer
D, Lansbury PT Jr.
Biochemistry. 2007 Jun 19;46(24):7107-18. Epub 2007 May 26.
Link to
PubMed Abstract.
Reversible monoubiquitination regulates the Parkinson disease-associated
ubiquitin hydrolase UCH-L1.
Meray RK, Lansbury PT Jr.
J Biol Chem. 2007 Apr;282(14):10567-75. Epub 2007 Jan 26. Link
to
PubMed Abstract.
Relationships between the sequence of alpha-synuclein and its membrane
affinity, fibrillization propensity, and yeast toxicity.
Volles MJ, Lansbury PT Jr.
J Mol Biol. 2007 Mar 9;366(5):1510-22. Epub 2006 Dec 21. Link
to
PubMed Abstract.
Dopamine affects the stability, hydration, and packing of protofibrils and
fibrils of the wild type and variants of alpha-synuclein.
Follmer C, Romão L, Einsiedler CM, Porto TC, Lara FA, Moncores M,
Weissmüller G, Lashuel HA, Lansbury P, Neto VM, Silva JL, Foguel D.
Biochemistry. 2007 Jan 16;46(2):472-82. Link to
PubMed Abstract.
Substrate recognition and catalysis by UCH-L1.
Luchansky SJ, Lansbury PT Jr, Stein RL.
Biochemistry. 2006 Dec 12;45(49):14717-25. Link to
PubMed Abstract.
A century-old debate on protein aggregation and neurodegeneration enters
the clinic.
Lansbury PT, Lashuel HA.
Nature. 2006 Oct 19;443(7113):774-9. Review. Link to
PubMed Abstract.
Improving synaptic function in a mouse model of AD.
Lansbury PT Jr.
Cell. 2006 Aug 25;126(4):655-7. Link to
PubMed Abstract.
Are amyloid diseases caused by protein aggregates that mimic bacterial
pore-forming toxins?
Lashuel HA, Lansbury PT Jr.
Q Rev Biophys. 2006 May;39(2):167-201. Epub 2006 Sep 18. Review.
Link to
PubMed Abstract.
Structural basis for conformational plasticity of the Parkinson's
disease-associated ubiquitin hydrolase UCH-L1.
Das C., Hoang Q.Q., Kreinbring C.A., Luchansky S.J., Meray R.K., Ray
S.S., Lansbury P.T., Ringe D., and Petsko G.A.
Proc Natl Acad Sci U S A. 2006 Mar 13; [Epub ahead of print]. Link
to
PubMed Abstract.
A computer program for the estimation of protein and nucleic acid sequence diversity in random point mutagenesis libraries. Volles M.J., Lansbury P.T., Jr. Nucleic Acids Res. 2005 Jun 29;33(11):3667-77. Link to PubMed (Open Access).
Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Ray, S.S., Nowak, R.J., Brown, R.H., Jr., and Lansbury, P.T., Jr. Proc Natl Acad Sci U S A. 2005 Mar 8; 102(10):3639-44. Link to PubMed Abstract.
Link to:
March 11, 2005 PNAS PDF
Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Cuervo, A.M., Stefanis, L., Fredenburg, R., Lansbury, P.T., and Sulzer, D. Science 2004 Aug 27;305(5688):1292-5. Link to PubMed Abstract.
Back to the future: the 'old-fashioned' way to new medications for neurodegeneration. Peter T. Lansbury, Jr. Nature Reviews Neuroscience 5, S51–S57 (2004).
Link to: Nature
Reviews Neuroscience PDF
Please Note: "Single copy of the article can be downloaded and printed for the reader's personal research and study."
"Reprinted from Nature Reviews Neuroscience 5, S51–S57 (2004), Peter T. Lansbury, Jr. Back to the future: the 'old-fashioned' way to new medications for neurodegeneration. Copyright 2004 Nature Publishing Group, with permission from Nature Publishing Group .
Source: Nature Publishing Group Page: http://www.nature.com/focus/neurodegen/index.html
Please note: Related articles can be found on the above web site.
Interactions Among alpha-Synuclein, Dopamine, and Biomembranes: Some Clues for Understanding Neurodegeneration in Parkinson's Disease. Rochet J.C., Outeiro T.F., Conway K.A., Ding T.T., Volles M.J., Lashuel H.A., Bieganski R.M., Lindquist S.L., and Lansbury P.T. J Mol Neurosci. 2004; 23(1-2):23-34. Link to PubMed Abstract.
A possible therapeutic target for Lou Gehrig's disease. Soumya S. Ray and Peter T. Lansbury, Jr. Proc Natl Acad Sci U S A. 2004 Apr. Link to PubMed.
An Intersubunit Disulfide Bond Prevents in Vitro Aggregation of a Superoxide Dismutase-1 Mutant Linked to Familial Amytrophic Lateral Sclerosis. Soumya S. Ray, Richard J. Nowak, Konstantin Strokovich, Robert H. Brown, Jr., Thomas Walz, and Peter T. Lansbury, Jr. Web Release Date: 06-Apr-2004; (Accelerated Publication) DOI: 10.1021/bi030246r
Ab protofibrils possess a stable core structure resistant to hydrogen exchange. Indu Kheterpal*, Hilal A. Lashuel*, Dean M. Hartley, Thomas Walz, Peter T. Lansbury Jr., and Ronald Wetzel. Biochemistry 42(48): 14092-14098. (Biochemistry 2003 ASAP; Web Release Date: 12-Nov-2003.) (*equal author work contribution). Link to PubMed Abstract.
Discovery of Inhibitors that Elucidate the Role of UCH-L1 Activity in the H1299 Lung Cancer Cell Line. Yichin Liu, Hilal A. Lashuel, Sungwoon Choi, Xuechao Xing, April Case, Jake Ni, Li-An Yeh, Gregory D. Cuny, Ross L. Stein, and Peter T. Lansbury. Chemistry and Biology, Vol 10, 837-846, September 2003. Link to PubMed Abstract.
Mixtures of Wild-type and a Pathogenic (E22G) Form of Ab40 in Vitro Accumulate Protofibrils, Including Amyloid Pores. Journal of Molecular Biology 2003 Sep 26;332(4):795. Hilal A. Lashuel, Dean M. Hartley, Benjamin M. Petre, Joseph S. Wall, Martha N. Simon, Thomas Walz and Peter T. Lansbury, Jr. Link to PubMed Abstract.
Dissociation of amyloid fibrils of {alpha}-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities. Foguel D., Suarez M.C., Ferrao-Gonzales A.D., Porto T.C., Palmieri L., Einsiedler C.M., Andrade L.R., Lashuel H.A., Lansbury P.T., Kelly J.W., and Silva J.L. Proc Natl Acad Sci U S A. 2003 Aug 4. Link to PubMed Abstract.
Zeroing in on the Pathogenic Form of alpha-Synuclein and Its Mechanism of Neurotoxicity in Parkinson's Disease. Michael J. Volles and Peter T. Lansbury, Jr. Biochemistry 2003 Jul 8;42(26):7871-8. Link to PubMed Abstract.
Protofibrils, Pores, Fibrils, and Neurodegeneration: Separating the Responsible Protein Aggregates from the Innocent Bystanders. Byron Caughey and Peter T. Lansbury, Jr. Annu Rev Neurosci. 2003 Apr 9 (epub ahead of print) Link to PubMed Abstract.
beta-Synuclein Inhibits Formation of alpha-Synuclein Protofibrils: A Possible Therapeutic Strategy against Parkinson's Disease. June-Young Park and Peter T. Lansbury, Jr. Biochemistry 2003 Apr 8;42(13):3696-700. Link to PubMed Abstract.
The N-Terminal Repeat Domain of alpha-Synuclein Inhibits beta-Sheet
and Amyloid Fibril Formation. Jeffrey C. Kessler, Jean-Christophe
Rochet, and Peter T. Lansbury, Jr. Biochemistry
2003 Jan 28;42(3):672-8. Link to
PubMed Abstract.
The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect alpha-Synuclein Degradation and Parkinson's Disease Susceptibility. Yichin Liu, Lara Fallon, Hilal A. Lashuel, Zhihua Liu, and Peter T. Lansbury, Jr. Cell 2002 Oct 18;111(2):209-18. Link to PubMed Abstract.
Link to:
CELL PDF
Please Note: "Single copy of the article can be downloaded and printed for the reader's personal research and study."
"Reprinted from Cell, Vol 111, Liu et al: The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect alpha-Synuclein Degradation and Parkinson's Disease Susceptibility, pp 209-118, Copyright 2002, with permission from Elsevier Science".
Cell Home Page: http://www.elsevier.com/locate/cell
Alpha-Synuclein, Especially the Parkinson's Disease-associated Mutants, Forms Pore-like Annular and Tubular Protofibrils. Hilal A. Lashuel, Benjamin M. Petre, Joseph Wall, Martha Simon, Richard J. Nowak, Thomas Walz, Peter T. Lansbury Jr. J Mol Biol 2002 Oct 4;322(5):1089. Link to PubMed Abstract.
Protofibrillar Islet
Amyloid Polypeptide Permeabilizes Synthetic Vesicles by a Pore-like
Mechanism that May Be Relevant to Type II Diabetes
Annular alpha-Synuclein Protofibrils Are Produced When Spherical
Protofibrils Are Incubated in Solution or
Bound to Brain-Derived Membranes. Tomas T. Ding, Seung-Jae Lee, Jean-Christophe
Rochet, and Peter T. Lansbury, Jr. Biochemistry 2002 Aug 13;41(32):10209-17. Link to
PubMed
Abstract.
Neurodegenerative disease: Amyloid pores from pathogenic mutations. Hilal A. Lashuel, Dean Hartley, Benjamin M. Petre, Thomas Walz, and Peter T. Lansbury Jr. Nature 2002 Jul 18;418(6895):291. Link to PubMed Abstract.
Link to:
Nature PDF
Genetics of Parkinson’s disease and biochemical studies of implicated gene products. Lansbury P.T., and Brice A. Curr Opin Genet Dev 2002 Jun;12(3):299-306. Link to PubMed Abstract.
Vesicle Permeabilization by Protofibrillar alpha-Synuclein Is Sensitive to Parkinson's Disease-Linked Mutations and Occurs by a Pore-like Mechanism. Volles M.J., and Lansbury P.T., Jr. Biochemistry. 2002 Apr 9;41(14):4595-602. Link to PubMed Abstract.
Molecular Crowding Accelerates Fibrillization of alpha-Synuclein: Could an Increase in the Cytoplasmic Protein Concentration Induce Parkinson's Disease? Shtilerman M.D., Ding T.T., and Lansbury P.T., Jr. Biochemistry. 2002 Mar 26;41(12):3855-60. Link to PubMed Abstract.
Link to:
Biochemistry Full Text
(Biochemistry free hot article in HTML and PDF formats.)
Kinetic Stabilization of the alpha-Synuclein Protofibril by a Dopamine-alpha-Synuclein Adduct. Conway KA, Rochet JC, Bieganski RM, Lansbury Jr PT. Science 2001 Nov 9;294(5545):1346-9. Link to PubMed Abstract.
Link to:
Science Full Text
(HTML and PDF formats.)
Vesicle Permeabilization by Protofibrillar alpha-Synuclein: Implications for the Pathogenesis and Treatment of Parkinson's Disease. Volles M.J., Lee S.J., Rochet J.C., Shtilerman M.D., Ding T.T., Kessler J.C., and Lansbury P.T., Jr. Biochemistry 2001 Jul 3;40(26):7812-9. Link to PubMed Abstract.
Following nature's anti-amyloid strategy. Lansbury P.T. Nat Biotechnol 2001 Feb;19(2):112-113. Link to PubMed Abstract.
An improved method of preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments. Fezoui Y., Hartley D.M., Harper J.D., Khurana R., Walsh D.M., Condron M.M., Selkoe D.J., Lansbury P.T., Fink A.L., and Teplow D.B. Amyloid 2000 Sep;7(3):166-78. Link to PubMed Abstract.
Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Rochet J.C., Conway K.A., and Lansbury P.T. Biochemistry 2000 Sep 5;39(35):10619-26. Link to PubMed Abstract.
Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Goldberg M.S., and Lansbury P.T Nat Cell Biol 2000 Jul;2(7):E115-9. Link to PubMed Abstract.
Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Conway K.A., Harper J.D., and Lansbury P.T. Biochemistry 2000 Mar 14;39(10):2552-63. Link to PubMed Abstract.
Amyloid fibrillogenesis: themes and variations. Rochet J.C., and Lansbury P.T. Curr Opin Struct Biol 2000 Feb;10(1):60-8. Link to PubMed Abstract.
Neurodegeneration: new clues on inclusions. Lansbury P.T., and Kosik K.S. Chem Biol 2000 Jan;7(1):R9-R12. Link to PubMed Abstract.
Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., and Lansbury P.T. Proc Natl Acad Sci U S A 2000 Jan 18;97(2):571-6. Link to PubMed Abstract.
Link to:
PNAS Full Text
(HTML and PDF formats.)
Methods for studying prion protein (PrP) metabolism and the formation of protease-resistant PrP in cell culture and cell-free systems. An update. Caughey B, Raymond G.J., Priola S.A., Kocisko D.A., Race R.E., Bessen R.A, Lansbury P.T., and Chesebro B. Mol Biotechnol 1999 Nov;13(1):45-55. Link to PubMed Abstract.
Yeast prions: bungee cord domains' balancing act. Lansbury P.T. Curr Biol 1999 Nov 18;9(22):R845-7. Link to PubMed Abstract.
Amyloid diseases: abnormal protein aggregation in neurodegeneration. Koo E.H., Lansbury P.T., and Kelly J.W. Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):9989-90. Link to PubMed Abstract.
Link to:
PNAS Full Text (HTML and PDF formats.)
Synthesis and amyloid binding properties of rhenium complexes: preliminary progress toward a reagent for SPECT imaging of Alzheimer's disease brain. Zhen W., Han H., Anguiano M., Lemere C.A., Cho C.G., and Lansbury P.T. J Med Chem. 1999 Jul 29;42(15):2805-15. Link to PubMed Abstract.
Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Harper J.D., Wong S.S., Lieber C.M., and Lansbury P.T. Biochemistry. 1999 Jul 13;38(28):8972-80. Link to PubMed Abstract.
Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Lansbury P.T. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3342-4. Review. No abstract available. Link to PubMed.
Link to:
PNAS Full Text (HTML and PDF formats.)
Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Conway K.A, Harper J.D., and Lansbury P.T. Nat Med. 1998 Nov;4(11):1318-20. Link to PubMed Abstract.
Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease. Lansbury P.T. Curr Opin Chem Biol. 1997 Aug;1(2):260-7. Review. Link to PubMed Abstract.